| Clarus Therapeutics Hldgs Inc (CRXT) | |||
|---|---|---|---|
| 0.0475 -0.022 (-31.16%) | 09-06 15:59 | ||
| Open: | 0.065 | Pre. Close: | 0.069 |
| High: | 0.0749 | Low: | 0.0475 |
| Volume: | 2,737,134 | Market Cap: | 0(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |   |
| Target: | Six months: 0.09 One year: 0.10 |
| Support: | Support1: 0.04 Support2: 0.02 |
| Resistance: | Resistance1: 0.07 Resistance2: 0.09 |
| Pivot: | 0.05 |
| Moving Averages: | MA(5): 0.05 MA(20): 0.04 MA(100): 0.16  MA(250): 0.95 |
| MACD: | MACD(12,26): Signal(12,26,9): |
| %K %D: | %K(14,3): 50.45 %D(3): 50.45 |
| RSI: | RSI(14): 53.62 |
| 52-Week: | High: Low: Change(%): -99.1 |
| Average Vol(K): | 3-Month: 1875 10-Days: 2737 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 0.07 - 0.07 | 0.07 - 0.071 |
| Low: | 0.049 - 0.05 | 0.05 - 0.05 |
| Close: | 0.05 - 0.05 | 0.05 - 0.05 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CRXT ] has closed below upper band by 43.3%. Bollinger Bands are 73% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 44 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 24.03 |
| Shares Float (M) | 32.02 |
| % Held by Insiders | 2.59 |
| % Held by Institutions | 23.28 |
| Shares Short (K) | 2000 |
| Shares Short Prior Month (K) | 3310 |
| Stock Financials | |
|---|---|
| EPS | -26.017 |
| Book Value (p.s.) | -1.170 |
| Profit Margin | -256.16 |
| Operating Margin | -271.72 |
| Return on Assets (ttm) | -89.5 |
| Return on Equity (ttm) | |
| Qtrly Rev. Growth | 72.1 |
| Gross Profit (p.s.) | 0.468 |
| Sales Per Share | 0.651 |
| EBITDA (p.s.) | -1.767 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -54.01 |
| Levered Free Cash Flow (M) | -43.12 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | -0.04 |
| Price to Sales | 0.07 |
| Price to Cash Flow | -0.02 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
